Drug & intervention

pimavanserin 34 MG

RxCUI 2049273

Clinical trials2

Recruiting0

Related conditions2

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

2 shown

Bioequivalence Study of Pimavanserin 34 mg CapsuleNCT06450184 · 2024-01-11

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)NCT02992132 · 2016-11-01

Conditions being studied

Agitation and Aggression in Alzheimer's Disease1 Parkinson Disease Psychosis1

Research locations

AlbuquerqueNew Mexico, United States1 AtlantaGeorgia, United States1 Boca RatonFlorida, United States1 CharlestonSouth Carolina, United States1 CharlotteNorth Carolina, United States1 CórdobaSpain1 FresnoCalifornia, United States1 FullertonCalifornia, United States1 JacksonMississippi, United States1 Los AngelesCalifornia, United States1 MadridSpain1 ManchesterUnited Kingdom1

Leading sponsors

ACADIA Pharmaceuticals Inc.1 Humanis Saglık Anonim Sirketi1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.